Lonza plans to ensure consistent product quality by incorporating Agilent’s analytics technology into its Cocoon platform.
Lonza and Agilent announced a strategic collaboration to incorporate new analytical technologies into Lonza’s Cocoon platform technology on Dec. 15, 2021. By incorporating analytical technology into Cocoon, an automated and closed platform for patient-scale cell therapy manufacturing, the companies hope to ensure consistent product quality.
According to a Lonza press release, product quality and consistency are difficult to maintain in cell therapy manufacturing due to product complexity and patient-specific variability. Additionally, minor manufacturing changes can result in major effects to quality and efficacy, making in-process controls and analytics critical in ensuring consistency.
To remedy this, Lonza plans to integrate Agilent’s analytics technologies and techniques into the Cocoon platform. These in-process controls and analytics will help provide real-time information on critical quality attributes (CQAs), with the ultimate goal of defining the ideal CQAs required for cell therapies.
“The integration of Agilent’s analytical technologies into the Cocoon [platform’s] manufacturing workflow has the potential to transform the way cell therapies are manufactured and released,” said Nicholas Ostrout, senior director, Business Strategy & Implementation, Personalized Medicine, Lonza, in the press release. “The collaboration with Agilent is complementary to our long-term goals for the Cocoon [platform] and we are excited about this synergistic relationship. There is a huge opportunity through this partnership to determine what the ideal critical quality attributes are for manufacturing the most effective cell therapy, and drive the manufacturing, optimally in real-time, to meet those criteria.”
“Merging Agilent’s unique cell analytics and engineering expertise with Lonza’s advanced biologics manufacturing capabilities will ensure the efficacious and sustainable development of autologous cell-based therapies,” said David Ferrick, associate vice-president, New Market Development, Cell Analysis Division, Agilent, in the press release. “This timely combination is well positioned to deliver the first fit-for-purpose solution for scaled manufacturing of autologous cell therapies.”
Source: Lonza
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.